FOI 2025/1498

I’m writing to you under the Freedom of Information Act 2000 to request the following information from NHS Greater Manchester ICB.
Please send your reply to me electronically, by email.
I would like to request the following information:
Please state:

1. How many individual patients within the ICB have been prescribed or dispensed Mounjaro (tirzepatide) since the start of the phased rollout on 23 June 2025?
2. If possible, please provide this data broken down by month.
3. If your ICB is not currently prescribing tirzepatide (Mounjaro), when will it be available?
4. How many patients within the ICB and associated specialist weight management services are currently being prescribed WeGovy (semaglutide)?
5. What BMI does someone need to have to be eligible for WeGovy (semaglutide) within the ICB and associated specialist weight management services?
6. Has that BMI eligibility for WeGovy (semaglutide) changed over time? If yes, please state by date when the change was made and what the BMI eligibility is/was.

1. For the four month period of June 2025 to September 2025, 8,605 patients have been prescribed Mounjaro (tirzepatide) within Greater Manchester ICB
2. The number of patients that have been prescribed Mounjaro (tirzepatide) within Greater Manchester ICB within each individual month are:
June 2025: 5,863
July 2025: 6,442
Aug 2025: 5,722
Sep 2025: 7,071
3. N/A
4. Using the latest data available, 19 patients were prescribed WeGovy (semaglutide) in the month of September 2025 within Greater Manchester ICB.
5. Please refer to the attached commissioning statement for eligibility criteria for WeGovy.
6. The attached commissioning statement was approved by ICB governance in September 2025.

** A PDF document was sent to the requester with this response.  If you require a copy of the full response, together with the document, please contact NHS GM’s FOI team – nhsgm.foi@nhs.net**